[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
July 2014

Estimating Overdiagnosis in Lung Cancer Screening—Reply

Author Affiliations
  • 1Department of Radiology, Duke University Medical Center, Durham, North Carolina
  • 2National Cancer Institute, Bethesda, Maryland

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2014;174(7):1198-1199. doi:10.1001/jamainternmed.2014.1525

In Reply We appreciate the letters by Drs Marcus, Couraud et al, and Gelbman and Libby in response to our recent study on estimating overdiagnosis in low-dose computed tomographic screening for lung cancer.1 We agree with Dr Marcus that not all cases of overdiagnosis in a cancer screening program are necessarily caused by indolent tumors and should have made this clearer in our article. Given the natural history of most clinically apparent lung cancers, however, we estimate that the majority of overdiagnosis cases in the National Lung Cancer Screening Trial (NLST) were indolent tumors but acknowledge that this may not be exactly the case in other cancers or in population-based screening programs, with extended follow-up.